BIOCRYST PHARMACEUTICALS, INC.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2021 | $-142.2M | $-144.5M | $2.4M | $34.6M |
| FY2022 | $-161.9M | $-163.2M | $1.4M | $44.7M |
| FY2023 | $-95.1M | $-97.3M | $2.2M | $55.6M |
| FY2024 | $-52.0M | $-53.1M | $1.1M | $65.4M |
| FY2025 | $347.4M | $344.9M | $2.5M | $85.1M |